{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:53:33Z","timestamp":1792166013562,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.medcli.2024.02.013","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T22:53:47Z","timestamp":1712962427000},"page":"e70-e73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?"],"prefix":"10.1016","volume":"162","author":[{"given":"Isabel","family":"Concei\u00e7\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2024.02.013_bib0260","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.medcli.2024.02.013_bib0265","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","article-title":"Evolving landscape in the management of transthyretin amyloidosis","volume":"47","author":"Hawkins","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.medcli.2024.02.013_bib0270","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13023-022-02359-w","article-title":"Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update","volume":"1","author":"Dispenzieri","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.medcli.2024.02.013_bib0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/mus.26034","article-title":"Estimating the global prevalence of transthyretin familial amyloid polyneuropathy","volume":"57","author":"Schmidt","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medcli.2024.02.013_bib0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.medcli.2024.02.013_bib0285","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1586\/14737175.2014.983905","article-title":"Current and future treatment of amyloid neuropathies","volume":"14","author":"Adams","year":"2014","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.medcli.2024.02.013_bib0290","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.02.013_bib0300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.02.013_bib0305","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2024.02.013_bib0310","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0315","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0320","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/13506120903090726","article-title":"Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation","volume":"16","author":"Drent","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0325","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/13506129.2020.1730790","article-title":"Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis","volume":"27","author":"Obici","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0330","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medcli.2024.02.013_bib0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.medcli.2024.02.013_bib0340","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/jnnp.53.6.522","article-title":"Restless legs syndrome and nocturnal myoclonus: initial clinical manifestation of familial amyloid polyneuropathy","volume":"53","author":"Salvi","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.medcli.2024.02.013_bib0345","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/13506129.2022.2052838","article-title":"Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis","volume":"29","author":"Ando","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0350","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jns.2009.05.001","article-title":"Familial amyloid polyneuropathy: a clinico-pathologic study","volume":"284","author":"Said","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.medcli.2024.02.013_bib0355","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0360","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s12325-022-02139-9","article-title":"Clinical and genetic evaluation of people with or at risk of hereditary ATTR amyloidosis: an expert opinion and consensus on best practice in Ireland and the UK","volume":"39","author":"Gillmore","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.medcli.2024.02.013_bib0365","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mus.25210","article-title":"Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy","volume":"54","author":"Schmidt","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medcli.2024.02.013_bib0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0375","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13506129.2022.2070470","article-title":"A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"29","author":"Coelho","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0380","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","article-title":"Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type","volume":"16","author":"Do Amaral","year":"2009","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0385","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/ene.15268","article-title":"Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis","volume":"29","author":"Leonardi","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0390","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acn3.51636","article-title":"Cutaneous amyloid is a biomarker in early ATTRv neuropathy and progresses across disease stages","volume":"9","author":"Freeman","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0395","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13023-020-01565-8","article-title":"Abdominal fat pad biopsies exhibit good diagnostic accuracy in patients with suspected transthyretin amyloidosis","volume":"15","author":"Paulsson Rokke","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.medcli.2024.02.013_bib0400","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.medcli.2024.02.013_bib0405","first-page":"217","article-title":"Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy","volume":"141","author":"Li","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0410","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.neucli.2015.09.012","article-title":"Diagnosis of small fiber neuropathy: a comparative study of five neurophysiological tests","volume":"45","author":"Lefaucheur","year":"2015","journal-title":"Neurophysiol Clin"},{"key":"10.1016\/j.medcli.2024.02.013_bib0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0924-980X(96)95662-3","article-title":"Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP)","volume":"101","author":"Montagna","year":"1996","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0420","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1007\/s00415-008-0962-z","article-title":"Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci","volume":"255","author":"Koike","year":"2008","journal-title":"J Neurol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0425","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurol.2016.08.007","article-title":"Familial amyloid polyneuropathy: when does it stop to be asymptomatic and need a treatment?","volume":"172","author":"Adams","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.medcli.2024.02.013_bib0430","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis \u2013 understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0435","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/ene.15176","article-title":"Changes in nerve conduction studies predate clinical symptoms onset in early onset Val30Met hereditary ATTR amyloidosis","volume":"29","author":"Castro","year":"2022","journal-title":"Eur J Neurol"},{"issue":"Suppl. 1","key":"10.1016\/j.medcli.2024.02.013_bib0440","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13506129.2019.1582503","article-title":"Early diagnostic tools in hereditary amyloidosis related to transthyretin (hATTR) V30M autonomic neuropathy","volume":"26","author":"de Campos","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/mus.23901","article-title":"Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy","volume":"49","author":"Concei\u00e7\u00e3o","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medcli.2024.02.013_bib0450","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/mus.10255","article-title":"Quantitative sensation testing in small-diameter sensory fiber neuropathy","volume":"26","author":"Dyck","year":"2002","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.medcli.2024.02.013_bib0455","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/13506129.2022.2155132","article-title":"Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?","volume":"30","author":"Concei\u00e7\u00e3o","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0460","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1093\/brain\/awz333","article-title":"Diagnostic criteria for small fibre neuropathy in clinical practice and research","volume":"142","author":"Devigili","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.medcli.2024.02.013_bib0465","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.21332","article-title":"Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy","volume":"40","author":"Dong","year":"2009","journal-title":"Muscle Nerve"},{"issue":"Suppl. 1","key":"10.1016\/j.medcli.2024.02.013_bib0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13506129.2019.1582494","article-title":"Correlation between Sudoscan and COMPASS 31: assessment of autonomic dysfunction on hATTR V30M patients","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0475","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.clinph.2016.02.013","article-title":"The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy","volume":"127","author":"Castro","year":"2016","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0480","first-page":"1","article-title":"Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis","volume":"26","author":"Azevedo Coutinho","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.medcli.2024.02.013_bib0485","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcmg.2014.03.007","article-title":"Early identification of transthyretin-related hereditary cardiac amyloidosis","volume":"7","author":"Arbustini","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Pt 3","key":"10.1016\/j.medcli.2024.02.013_bib0490","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/brain\/awu344","article-title":"In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography","volume":"138","author":"Kollmer","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.medcli.2024.02.013_bib0495","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/acn3.51049","article-title":"Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis","volume":"7","author":"Kollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.medcli.2024.02.013_bib0500","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy MR neurography vs clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.medcli.2024.02.013_bib0505","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jns.12350","article-title":"Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis","volume":"24","author":"Kapoor","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.medcli.2024.02.013_bib0510","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13506129.2019.1708716","article-title":"Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy","volume":"27","author":"Maia","year":"2020","journal-title":"Amyloid"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532400160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002577532400160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T09:11:17Z","timestamp":1718442677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002577532400160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S002577532400160X"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2024.02.013","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early diagnosis in ATTRv amyloidosis, how early is enough? How early is possible?","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2024.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}